Prasad Suyash
- SEC CIK
- 0001679129
No open-market purchases or sales filed in the past year.
Current role at each company
- TSHA Taysha Gene Therapies, Inc.CMO and Head of R&Das of Jul 7, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Prasad Suyash as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2022 (view filing) | Jul 5-6 | 2 days | Prasad SuyashCMO and Head of R&D | SSale | −12.9K | $3.70 | −$47.6K | −2.4%530.6K after | 2 lots |
| Jul 1, 2022 (view filing) | Jun 29-Jul 1 | 2 days | Prasad SuyashCMO and Head of R&D | SSale | −50.1K | $3.65 | −$183.1K | −8.4%543.5K after | 3 lots |
| Jul 1, 2021 (view filing) | Jun 29-Jul 1 | 2 days | Prasad SuyashCMO and Head of R&D | SSale | −79.0K | $22.63 | −$1.79M | −11.7%593.6K after | 7 lots |